Picture supply: Getty Pictures
UK traders have quite a lot of shares to select from on the FTSE 100. Development shares promise excessive returns, dividend shares pay common earnings and worth shares recognize over time. And don’t neglect defensive shares, offering a buffer when the economic system goes crazy!
By developing a well-balanced portfolio of various shares, traders can cut back threat and intention for secure development over time.
I’m at all times looking out for brand spanking new and promising shares to boost my portfolio. So listed here are three I plan to purchase in October.
Development
I thought-about shopping for JD Sports activities Vogue (LSE: JD.) shares earlier this yr however determined towards it. Quickly after, the corporate issued a revenue warning and the worth spiralled! The warning was because of considerably decrease spending in 2023 because of inflation.
Sports activities and vogue are each areas shoppers have a tendency to cut back spending on when cash’s tight. Issues are bettering now however one other upset might damage the corporate’s income once more.
So with the worth up by 50% since February, is now the time to purchase? Goldman Sachs thinks so — the dealer put in a Purchase score on the inventory final month.
Its metrics look good too. The price-to-earnings (P/E) ratio’s 15.4 and the price-to-sales (P/S) ratio is 0.8. It’s additionally buying and selling at 32% beneath truthful worth, primarily based on future money movement estimates.
That each one suggests sturdy development potential, in my view.
Dividends
Rio Tinto‘s (LSE: RIO) a UK-based mining conglomerate with operations in Africa and Australia. It’s a 151-year-old firm with an £80bn market-cap, so it’s pretty well-established. That makes it a extra dependable selection for long-term dividends.
At 6.8%, it has the ninth highest yield on the FTSE 100. Dividends have elevated at a median fee of 14.62% a yr for the previous 15 years.
However whereas the dividends look good, value development might be in danger. With 60% of the corporate’s income coming from China, the stifled Asian economic system there might damage its income. This has been famous by analysts, who forecast earnings per share (EPS) to say no at a fee of 0.8% a yr.
If that will get worse it might threaten future dividends however, for now, it appears like a terrific earner to me.
Defensive
AstraZeneca‘s (LSE: AZN) the most important firm on the Footsie with a market-cap of £185bn. The pharma large has a really secure value with minimal volatility throughout financial crises. It additionally has comparatively gradual development, rising at an annualised fee of 5% a yr since 2014. These are each frequent attributes of a defensive share.
Patent expiry’s a typical threat with pharmaceutical firms and might result in income loss. AstraZeneca has poured cash into R&D to mitigate this threat nevertheless it’s ever-present.
In July, it posted reasonable Q2 outcomes with a 13% improve in income and 6% earnings development. Earnings-per-share (EPS) got here in barely beneath analyst expectations and revenue margins fell by 1%. However as a defensive share, I don’t count on spectacular development from AstraZeneca — solely that its secure value permits me calm and restful sleep patterns.
